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Franklin Ingram: It’s awfully hard to convince teenagers
that they can suffer any adverse effects from using
alcohol or other drugs. Adolescents all think they are
bulletproof. They think injury and death can happen
to other kids, but not themselves.
Joe Richard: One thing I have noticed about adoles-
cents is that they are very resilient, especially their
bodies; they can bounce back from overdoses and trau-
mas. I also think they are a lot more accessible than
adults. Not all of them, but as a group they seem to
be more amenable to exploring the possibility that
they have a problem. And they have a lot more con-
nections than adults. A lot of adults have burned their
bridges and they don’t have as much support.
Patricia Chandler: One obvious thing about ado-
lescents is that we have their parents to contend with.
They are usually a huge factor in the exacerbation
of the illness. And often that is a big roadblock.
Ingram: I have noticed that a very high percentage
of the adolescents we work with, at age 14 or so, have
a parent or guardian who also has a drug problem.
Chandler: That brings up an issue: A huge number
of these kids, especially the girls, have been sexually
abused. Abuse is common, and right now there is not
much effective help available for these individuals.
Ingram: For some kids we ought to come up with
something other than family treatment, because the
family is what has wounded them so badly.
Treating comorbid disorders
Ingram: What is most important to me about this
subject and this article is the increased efficacy we
would get if we actually treated patients’ comorbid
conditions along with their substance abuse disor-
ders. That is locally lacking in most adolescent sub-
stance abuse outpatient programs I know about.
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Several years ago I became involved with a pri-
vate, nonprofit adolescent residential program in
Greensboro, North Carolina, whose funding was
mainly a community effort. The program ran very
successfully for a while, serving 28 adolescents, but
then the census dropped to 4 and the Board became
alarmed, and I was brought in on an interim basis. 
My analysis—and of course I consulted experts—
was that we needed to do a much better job of address-
ing all of these comorbid conditions and strength-
ening our family program. Once we employed a
psychiatrist who diagnosed and medicated the comor-
bid conditions, we realized a significant improvement
in the adolescents’ staying in treatment and benefit-
ing from treatment. When I left a year and a half later,
the facility had a census of 24.
Richard: I liked Dr. Riggs’ suggestion to develop two
history timelines, one for the development of the ado-
lescent patient’s psychiatric symptoms and a separate
one for his or her drug use. That is definitely 
useful.
These patients will just overwhelm you diag-
nostically. How do you diagnose bipolar disorder
when someone has been bingeing on crank 2 weeks
every month for the past 3 years? This is one red
flag I think we need to throw up for clinicians: It is
very difficult to use history and even behaviors to
make an accurate diagnosis. For example, consider
someone who’s been snorting 12 to 15 anxiolytics
every day and washing them back with alcohol. He
or she is definitely going to have some withdrawal
coming off the anxiolytics and also going to have some
secondary withdrawal. It is almost impossible, even
in 45 days, to make an accurate diagnosis of attention-
deficit disorder for this person. There is a host of sub-
stances that will interfere with an accurate diagnosis.
Chandler:  Dr. Riggs mentions the lack of training
among substance use providers concerning medica-
tion management for the comorbid psychiatric dis-
orders. My experience has been that there is a lack of
education among child psychiatrists in the area of
addiction medicine. They tend to have preconceived
notions about what substance abuse treatment should
be, totally disregarding the few evidence-based treat-
ments we have available.
Richard: We have an attending physician who is an
addictionologist, who also does a lot of prescribing
of psychotropic medications with our clients who are
having psychiatric problems and also reevaluating
clients who are on numerous medications. It is not
unusual; maybe 50 percent of clients are on two or
more medications when they come to us.
Ingram: At SouthLight, we have two psychiatrists
working with our staff, neither of whom wants to pre-
scribe medications directly. They want to refer patients
with comorbid conditions to outside psychiatrists to
follow them on their medication. They don’t want to
be on call if there is an adverse effect. They don’t think
our staff is sufficiently trained to spot signs of 
trouble.
Chandler: As a medical person, I would say that if
you have staff members capable of achieving a mas-
ter’s degree in substance abuse counseling, it won’t
take much to teach them the side effects of medica-
tion. Most of them get some of this information along
the way anyhow. I think you need people who are
smart, and you could do it in a 2- or 3-day workshop.
Richard:  I wonder if you have thought of the possi-
bility of having a nurse or a physician’s assistant coor-
dinate between the psychiatrist and the counselors.
We have a number of psychiatric nurses on our staff
who do a really nice job of monitoring target symp-
toms and educating for side effects as well.
Chandler: That would be ideal.
Ingram: The problem for me is, on the outpatient basis,
who can afford that?  It’s financially impossible.
Richard: Dr. Riggs raises a very interesting issue con-
cerning the practice of getting patients abstinent from
their drugs of abuse before starting them on medica-
tions for comorbid disorders. I would say 25 percent
of our clients come from another facility where they
have undergone psychiatric evaluation. We auto-
matically keep them on those medications.
On the other hand, some physicians will take
kids off the medications before they get here because












may be abusing. They might have been on an anti-
depressant or some regimen for bipolar disorder, and
all their medications are discontinued. Then we start
them again on those medications. There are many dif-
ferent scenarios with different outcomes. There are
no black and white answers.
Chandler: Dr. Richard, what if a kid comes in with
a strong family history of depression and depressive
symptoms that predate the use of substances? I would
be more inclined to start that patient on an antide-
pressant immediately, rather than waiting to sort out
whether or not the depression is substance-induced.
Richard: If the patient has recently been suicidal, we
don’t wait. That is our rule of thumb.
Chandler: And if there is no suicidality, would you
consider it in these kids who you are pretty certain
have an underlying depressive disorder? I worry about
withholding treatment from kids who might do
better in programs if they were medicated from the
get-go.
Richard: We don’t wait much longer than a week.
Our attending physician joins our staff meetings every
Thursday.
Chandler: Dr. Riggs emphasizes lithium as a mood
stabilizer. I’m concerned as a primary care physician
who takes care of people later on in life and sees enor-
mous problems with this medication. We have many
years of experience with other medications, such as
Depakote, that do not have the same renal toxicity,
for when a kid needs a mood stabilizer.
Richard: Dr. Riggs characterizes pemoline [Cylert]
as having lower abuse potential than other stimulants
for ADHD. That may be true, but kids snort it,
they sell it, they trade it for illicit drugs. Is anyone
familiar with atomoxetine [Strattera]? It’s a very
new nonaddictive, nonstimulant medication for
ADHD. We have one client on it, and he’s doing very
well.
Around 25 percent of our kids have sleep prob-
lems coming in, and had them before they ever used
drugs. As an inpatient facility, we have the luxury of
observing whether they are medication-seeking when
they report sleep problems. If they really are sleeping
fitfully or not at all, there is a recommendation for
sleep medication, usually trazodone [Desyrel]. When
individuals sleep they are able to function at a much
higher level and participate in therapy much better.
12-step responses and funding
Chandler: I’m in the thick of the Bible Belt. I find
that some of these adolescent patients hold on to fun-
damental Christian beliefs, and for them AA is very
good.
Ingram: In my experience, if you are going to rely on
12-step programs and groups, make sure the adoles-
cent gets involved with a group that has some long-
term recovery. I have seen kids and adults get in NA
and AA groups where there is no long-term recovery,
and it just turns into a disaster.
Chandler: I have a question. Almost all of these kids
have family members who are also abusing substances.
How much emphasis do you put on the codependency
model, which a lot of psychiatrists say is just pop psy-
chology? Sometimes people have had a lot of success
with that.
Ingram: Both my father and my stepfather were alco-
holic. In my own experience, even though I didn’t use
alcohol or drugs, I found AA more helpful than Alateen.
I don’t know if Alateen is particularly helpful for some-
body who is dealing with their own alcohol or drug
issues. From my personal experience, I was much more
inspired by the recovery stories in AA. Just my 
opinion.
Richard:  We use Al-Anon here. A lot of our kids have
alcoholic or drug-addicted close family members.
Some of these kids just seem to come from Mars into
these families. It’s devastating for them and they don’t
have a clue about what these kids are going through
when they are in treatment. Al-Anon really helps.
Ingram: I have tried to set up self-sustaining ado-
lescent treatment programs. I think it is virtually
impossible to sustain a really good adolescent sub-
stance abuse treatment program, to say nothing of
one that also treats comorbid disorders, without a big
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United Way, and so on. There is no way families can
pay for this out of pocket. The amount of third-party
payments available for this purpose is minuscule.
Chandler: The only bright point is that I think it is
easier to advocate for funds for adolescent treat-
ment than adults. Legislatures, policymakers in
general are more willing to provide money for ado-
lescents than for adults.
Ingram: I agree, particularly if you have a family 
program.
Richard: Every time I go to a conference, clinicians
tell me, ‘You’re not going to have a program there next
year.’ I have been here 9 years now and people have
told me that every year. But there is a Federal man-
date that States be able to provide residential treat-
ment for adolescent substance abuse-dependent indi-
viduals. From what I’m told, a lot of States, and a
lot of programs in a lot of States, have monies avail-
able that they may not be using. &
Around 25% of
our kids have
sleep problems
coming in, and
had them
before they ever
used drugs.